Business Wire

Sagemcom’s Net Zero Trajectory Approved by SBTi: Target Set for 2040

Share

Sagemcom Group has today reached a critical milestone in its climate strategy: its Net Zero carbon target for 2040—encompassing all activities and sites within the Group’s consolidated scope—has been officially validated by the Science Based Targets initiative (SBTi).

This international endorsement attests to the scientific rigor of Sagemcom’s decarbonization strategy, aligned with the Paris Agreement’s ambition to limit global warming to 1.5°C. It strengthens the Group’s comprehensive climate roadmap, which is built on a significant reduction of greenhouse gas emissions across all scopes:

  • By 2030:
    • A 47% absolute reduction in Scope 1 and Scope 2 emissions (direct emissions and purchased energy),
    • 100% renewable energy consumption across all Group sites,
    • A 31% absolute reduction in Scope 3 emissions, including those related to the value chain, with no exclusion of any greenhouse gas categories.
  • By 2040:
    • Achievement of Net Zero, corresponding to a 90% absolute reduction in total Group emissions compared to the 2019 baseline.

Sagemcom’s strategy—based 95% on physical activity data—relies on concrete and actionable levers: transitioning to renewable energy sources, eco-design of products and services, engagement with stakeholders across the value chain, and integration of climate-related issues into all levels of the Group’s operations.

A Recognition of the Group’s Collective Commitment

“For several years, Sagemcom has been deploying a structured strategy to reduce its carbon footprint. These efforts became statutory in February 2022, when the Group adopted the status of ‘Entreprise à mission’,” said Sylvaine Couleur, Executive Vice-President CSR & Communication. “The validation by the SBTi serves as a strong recognition of the work carried out by our teams and the substantial investments made by the Group in collaboration with our clients and suppliers. It also sends a clear message to all stakeholders: we are fully committed to the fight against climate change, with determination and transparency, in accordance with a clearly defined, shared, and scientifically validated roadmap.”

About Sagemcom

Thanks to the innovative solutions designed and built by our people, Sagemcom provides access to broadband Internet, entertainment and managed energy supply to the greatest number all over the world.

As a “mission-driven company” since January 2022, Sagemcom makes sure that the design, construction and use of these solutions are sustainable, and fulfil the environmental and societal commitments that are known and shared by all our employees, partners and stakeholders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250623571504/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Grid Dynamics Announces AI-Powered Engagement Model Enabling Accelerated Business Transformation for Fortune 1000 Enterprises23.6.2025 15:15:00 CEST | Press release

Key Takeaways: Grid Dynamics introduces an AI-powered engagement model for software delivery. This engagement model expands Grid Dynamics’ offerings by providing a fundamentally new way of delivering value—enabling clients to achieve superior outcomes by providing the next level of agility, quality, and accelerated time-to-market. The model is based on the Grid Dynamics AI-Native Development Framework (GAIN Development Framework)—a combination of proprietary processes, human capital, and an AI-Enabled Development Platform. This framework is designed specifically to support the scale and complexity of Fortune 1000 enterprises. Based on internal benchmarks, we expect this model to accelerate project delivery by achieving over 30% productivity improvements. Progressive credit-based pricing directly tied to performance and value is the basis of the new engagement model. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics)—a prominent technology consulting and digital services provid

Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges23.6.2025 14:05:00 CEST | Press release

As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623205345/en/ LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain. According to Novotech’s analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities. Highli

One, Two, Three-Peat: Mary Kay Inc. Named #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World for Three Years in a Row23.6.2025 14:00:00 CEST | Press release

Good things come in threes: iconic beauty brand and global entrepreneurship company Mary Kay Inc. has again been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World1 by Euromonitor International for the third consecutive year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623000452/en/ Ryan Rogers, Chief Executive Officer of Mary Kay states: "Being named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World by Euromonitor International three years in a row marks a grand slam achievement for Mary Kay. This repeated milestone reflects years of R&D and marketing efforts to create skin and beauty solutions that meet consumer needs and are loved the world-over. Above all, it demonstrates the transformative power of our Independent Beauty Consultants who are driving this success globally." (Photo Courtesy: Mary Kay Inc.) Euromonitor International is the foremost provider of globa

Fujirebio Acquires Plasma Services Group and Strengthens Its Position as Provider of Critical and High Quality Biological Raw Materials to the IVD and Life Science Industries23.6.2025 13:00:00 CEST | Press release

H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio, has acquired all shares of Plasma Services Group, Inc. (hereinafter “Plasma Services Group”). The transaction value has not been disclosed. Founded in 2004, Plasma Services Group has specialized in the collection, screening and supply of high quality and rare biological materials required for R&D and manufacturing in the in vitro diagnostics (IVD) and life science industries. The company is particularly well positioned in the field of rare diseases. From its state-of-the-art FDA registered, ISO certified facility in Moorestown, NJ, USA, Plasma Services Group provides sera and other samples for materials of control reagents and calibrators for a wide range of diseases and offers sample collection services globally. For more information about Plasma Services Group please visit www.plasmaservicesgroup.com

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression23.6.2025 12:30:00 CEST | Press release

A single administration of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS1 with a mean difference of -3.6 comparing 25 mg to placebo (p<0.001)2Independent Data Safety Monitoring Board (DSMB) reviewed safety data for COMP360 and found no unexpected safety findings and no clinically meaningful imbalance in suicidal ideation between treatment and placebo armsOngoing pivotal Phase 3 COMP005 trial is the first study of an investigational, synthetic psilocybin, and the first classic psychedelic3, to report Phase 3 efficacy dataSecond ongoing pivotal Phase 3 COMP006 trial continues to enroll well, with 26-week data expected in the second half of 2026 Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP005 trial, the first of two Phase 3

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye